Drug intelligence / Profile preview

BT4

Development stage: Preclinical
Lead developer: Bycus Therapeutics
Modality: Therapeutic Enzymes → Recombinant Proteins and Enzymes

Overview

BT4 is a protease enzyme currently in early-stage development by Bycus Therapeutics. It is part of the company's specialized pipeline of therapeutic enzymes, which includes both nucleases and proteases. As a protease, BT4 is designed to catalyze the site-specific proteolytic cleavage of target proteins to achieve a therapeutic effect. While Bycus Therapeutics focuses on therapeutic areas such as infectious diseases, metabolic disorders, and oncology, the specific molecular target and primary clinical indication for BT4 have not yet been publicly disclosed.

Beyond the preview

Go deeper on BT4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BT4.

Explore the full profile